ACM
IOVA icon

Ayer Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Ayer Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		$25.9M Sell
2,823,333
-2,780,682
-50% -$31M 96.51% 1
2015
Q1 		$67.9M Buy
+5,604,015
New +$63.1M 99.4% 1

Other funds holding IOVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ayer Capital Management's IOVA Position: Q2 2015 in Review

Ayer Capital Management reduced its Iovance Biotherapeutics (IOVA) stake by 50% in Q2 2015, selling an estimated $31M and leaving 2,823,333 shares worth $25.9M. The position accounts for 96.51% of the portfolio, ranked #1.

Ayer Capital Management first reported a position in IOVA in Q1 2015 and has held it in 2 quarters since. The position peaked at $67.9M in Q1 2015. 86 funds tracked by Wall St. Rank hold IOVA as of Q2 2015.

  • Ayer Capital Management held 2,823,333 shares of Iovance Biotherapeutics worth $25.9M as of Q2 2015.
  • Ayer Capital Management sold 2,780,682 Iovance Biotherapeutics shares in Q2 2015, an estimated $31M.
  • Iovance Biotherapeutics made up 96.51% of Ayer Capital Management's portfolio in Q2 2015, its #1 holding.
  • Ayer Capital Management first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 2 quarters since.
  • Ayer Capital Management's Iovance Biotherapeutics position peaked at $67.9M in Q1 2015.
  • 86 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2015.

Based on Ayer Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.